Compare THR & AKBA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | THR | AKBA |
|---|---|---|
| Founded | 1954 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 879.5M | 729.1M |
| IPO Year | 2011 | 2014 |
| Metric | THR | AKBA |
|---|---|---|
| Price | $36.07 | $1.52 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $6.25 |
| AVG Volume (30 Days) | 301.7K | ★ 5.1M |
| Earning Date | 11-06-2025 | 11-10-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 36.04 | N/A |
| EPS | ★ 1.75 | N/A |
| Revenue | ★ $509,054,000.00 | $225,071,000.00 |
| Revenue This Year | $2.56 | $52.38 |
| Revenue Next Year | $6.31 | $22.45 |
| P/E Ratio | $20.38 | ★ N/A |
| Revenue Growth | 3.08 | ★ 32.49 |
| 52 Week Low | $23.05 | $1.45 |
| 52 Week High | $36.14 | $4.08 |
| Indicator | THR | AKBA |
|---|---|---|
| Relative Strength Index (RSI) | 70.95 | 32.24 |
| Support Level | $34.70 | $1.45 |
| Resistance Level | $35.50 | $1.63 |
| Average True Range (ATR) | 1.09 | 0.10 |
| MACD | -0.04 | 0.02 |
| Stochastic Oscillator | 97.50 | 20.25 |
Thermon Group Holdings Inc is a United States-based company that provides engineered industrial process heating solutions for process industries. It offers a full suite of products (heating units, electrode and gas-fired boilers, heating cables, industrial heating blankets and related products, temporary power solutions and tubing bundles), services (engineering, installation and maintenance services) and software (design optimization and wireless and network control systems) required to deliver comprehensive solutions to some of the world's Large and most complex projects. Its products and services include a wide range of electric heat tracing cables, steam heating solutions, controls, monitoring and software, instrumentation, project services, industrial heating and filtration solutions.
Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics for people with kidney disease. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease, Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor approved in Japan for the treatment of anemia due to chronic kidney disease, in adult patients, HIF-PH inhibitors in preclinical development.